证券代码：603456 证券简称：九洲药业 公告编号：2025-055 浙江九洲药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 通过分配方案的股东会届次和日期 浙江九洲药业股份有限公司（以下简称"公司"）2025 年 5 月 8 日的2024年 年度股东大会授权董事会在符合利润分配条件的情况下制定具体的分配方案，本 次利润分配方案经 2025 年 8 月 5 日召开的第八届董事会十六次会议审议通过。 二、 分配方案 ? 每股分配比例 A 股每股现金红利0.20元。 ? 相关日期 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放日 Ａ股 2025/9/5 － 2025/9/8 2025/9/8 ? 差异化分红送转：是 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》（以下简称"公司法"）、《中华人民共和国证 券法》（以下简称"证券法"）、《上海证券交易所上 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年半年度差异化权益分派事项的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 0 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年半年度差异化权益分派事项的 法律意见书 编号：TCYJS2025H1364 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2025 年半年度利润分配方案所 涉及的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中 华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股份回购规则》（以下简称"《回购规 三、本所律师对与出具本法律意见书有关的所有文件、资料等进行了合理核查、 判断，并据此发表法律意见。对本法律意见书至关重要而又无法得到独立的证据支 持的事实，或者基于本所专业无法作出核查及判断的重要事实，本所依赖政府有 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-055 浙江九洲药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/5 | － | 2025/9/8 | 2025/9/8 | 差异化分红送转：是 一、 通过分配方案的股东会届次和日期 浙江九洲药业股份有限公司（以下简称"公司"）2025 年 5 月 8 日的2024年 年度股东大会授权董事会在符合利润分配条件的情况下制定具体的分配方案，本 次利润分配方案经 2025 年 8 月 5 日召开的第八届董事会十六次会议审议通过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分 ...

资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 9月1日，九洲药业涨5.14%，截至发稿，报19.02元/股，成交5.94亿元，换手率3.61%，总市值169.17亿 元。 截至发稿，葛兰累计任职时间10年219天，现任基金资产总规模399.08亿元，任职期间最佳基金回报 125.88%， 任职期间最差基金回报-35.13%。 赵磊累计任职时间60天，现任基金资产总规模308.01亿元，任职期间最佳基金回报13.75%， 任职期间 最差基金回报13.59%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）二季度 减持438.84万股，持有股数1342.63万股，占流通股的比例为1.51%。根据测算，今日浮盈赚取约1248.65 万元。 中欧医疗健康混合A（003095）成立日期 ...

Core Viewpoint - Jiuzhou Pharmaceutical announced a capital increase of 200 million yuan for the construction of an innovative drug CDMO production base in Taizhou, with the project being implemented by Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. [1] Group 1 - The company will hold the 16th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on August 5, 2025 [1] - The capital increase is aimed at supporting the first phase of the construction project [1] - Jiuzhou Pharmaceutical (Taizhou) has completed the business registration change and obtained a new business license from the Market Supervision Administration of Linhai City [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-054 7、成立日期：2021 年 2 月 14 日 浙江九洲药业股份有限公司 关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第 八届董事会第十六次会议和第八届监事会第十次会议，审议通过了《关于使用部 分募集资金向募投项目实施主体增资实施募投项目的议案》，同意公司以募集资 金 20,000 万元对"九洲药业（台州）有限公司创新药 CDMO 生产基地建设项目 （一期工程）"实施主体九洲药业（台州）有限公司（以下简称"九洲药业（台 州）"）进行增资。具体内容详见公司于 2025 年 8 月 6 日在《上海证券报》和上 海证券交易所网站披露的相关公告（公告编号：2025-050）。 近日，九洲药业（台州）已完成工商变更登记手续，并取得临海市市场监督 管理局换发的《营业执照》，现将有关情况公告如下： 1、公司名称：九洲药业（台州）有限公司 2、统一社会信 ...

截至2025年8月21日收盘，九洲药业股价报18.43元，较前一交易日下跌0.16元，跌幅0.86%。当日成交 量为254225手，成交金额达4.68亿元。 公开信息显示，中欧医疗健康基金在2025年二季度对九洲药业进行了减持操作，持股数量减少438.84万 股。该基金由知名基金经理葛兰管理，目前仍位列公司前十大流通股东。 九洲药业是一家专注于化学制药领域的医药企业，主要从事原料药及中间体的研发、生产和销售。公司 产品涵盖抗感染类、心血管类、中枢神经类等多个治疗领域。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 从资金流向来看，8月21日九洲药业主力资金净流出8327.52万元，近五个交易日累计净流出2亿元。 ...

Core Insights - The article highlights the significant stock adjustments made by the China Europe Medical Health Fund, managed by Ge Lan, during the second quarter of 2025, particularly its increased holdings in several pharmaceutical companies [1][3][4]. Group 1: Fund Adjustments - The China Europe Medical Health Fund entered the top ten circulating shareholders of Lizhu Group and Betta Pharmaceuticals, holding 5.939 million shares and 4.3513 million shares, respectively [3]. - The fund significantly increased its stake in XinNuoWei by approximately 14 million shares, representing a 222% increase, bringing its total holdings to 20.184 million shares [3][4][6]. - Other notable increases included holdings in XinLiTai (up 86% to 26.163 million shares), NuoCheng JianHua (up 43.9% to 13.048 million shares), and HuaDong Pharmaceutical (up 17.39% to 24.4395 million shares) [4][6]. Group 2: Fund Management Strategy - In July, the China Europe Medical Health Fund announced the appointment of Zhao Lei as a co-manager, indicating a shift towards a team-based management approach [8]. - The fund is part of a broader trend within China Europe Fund to enhance its research and investment management capabilities through a "professional, industrialized, and intelligent" investment research system [8][9]. - This transformation aims to create a sustainable organization capable of generating alpha over the long term, thereby improving product offerings and services for investors [9].

Group 1: Market Overview - The A-share market is currently active, with brokerage analysts conducting extensive research on listed companies as half-year reports are being disclosed [1][2] - A total of 162 companies have been researched by brokerages since August, covering popular sectors such as electronics, pharmaceuticals, machinery, and power equipment [1][2] Group 2: Sector Focus - The electronics, machinery, and pharmaceutical sectors are the most researched, with 22, 20, and 21 companies respectively [2] - The pet sector, particularly Zhongchong Co., Ltd. (002891), has attracted the most attention, with 61 brokerages participating in its recent performance briefing [2][3] Group 3: Company Highlights - Zhongchong Co., Ltd. has established over 22 modern production bases globally and is expanding its projects in various countries, including the US and Canada [3] - Ninebot Inc. has garnered interest from 47 brokerages, focusing on its electric two-wheeler profit margins and the development of its intelligent ecosystem [3] - Jerry Holdings (002353) has been researched by 41 brokerages, with a focus on its business structure and overseas market development [3] Group 4: Pharmaceutical Sector Insights - The pharmaceutical sector has seen significant interest, with over 65 research reports published in August, including 10 deep-dive reports [4] - Companies like Jiuzhou Pharmaceutical (603456) and Sanxin Medical (300453) have been actively researched, with Jiuzhou reporting a net profit of 526 million yuan, a 10.7% increase year-on-year [4][5] - Bo Rui Pharmaceutical has seen its stock price rise over 277% this year, with plans to expand its product offerings globally [5] Group 5: Rating Adjustments - Brokerages have upgraded the ratings of seven companies since August, including Aisheng Co., Ltd. (600732) and Huaneng International (600011) [6] - Huaneng International reported a net profit of 9.262 billion yuan, a 24.26% increase, prompting an upgrade to "buy" rating [6] - One stock, Fuling Pickles (002507), was downgraded from "buy" to "hold" due to slower sales recovery and increased cost pressures [6]

Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced the use of idle raised funds for cash management, amounting to 200 million RMB, to enhance fund efficiency while ensuring the safety and proper use of the funds [2][4]. Summary by Sections Cash Management Overview - The cash management is aimed at improving fund efficiency and ensuring the safety of the raised funds while not affecting the investment projects [4]. - The total amount allocated for cash management is 200 million RMB [5]. - The funds are sourced from a non-public stock issuance approved by the China Securities Regulatory Commission, raising approximately 2.5 billion RMB [6][7]. Cash Management Details - The cash management products include high-security and liquid investment options such as structured deposits, time deposits, large certificates of deposit, and wealth management products [2][9]. - The cash management period is set for a maximum of 12 months, with individual investment products not exceeding 12 months [2][9]. - The company has previously redeemed cash management products amounting to 21 million RMB, which were returned to the special account for raised funds [3]. Approval Process - The cash management proposal was approved during the 11th meeting of the 8th Board of Directors and the 7th meeting of the 8th Supervisory Board on December 13, 2024 [9]. - The management is authorized to make investment decisions within the approved limits and timeframes [9]. Impact on the Company - The cash management will not affect the normal operation of the company or the implementation of investment projects, ensuring no harm to the interests of the company and its shareholders [14]. - The income generated from cash management will belong to the subsidiary and will be returned to the special account for raised funds upon maturity [8][14].